MentionFox
Home › Executive changes › Dermata Therapeutics, Inc.
Leadership changes · DRMA · SEC Form 8-K, Item 5.02

Leadership changes at Dermata Therapeutics, Inc. (2026)

Before you join, sell to or invest in Dermata Therapeutics, Inc.

MentionFox check on Dermata Therapeutics, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/dermata-therapeutics

Check Dermata Therapeutics, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Dermata Therapeutics, Inc.?

Who joined and who left Dermata Therapeutics, Inc. (DRMA)? 1 departure reported on 2026-02-25, each cited to the company's own filing.

As of November 14, 2026, Dermata Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 25, 2026, naming 1 departure. The latest filing names Mary Fisher, leaving (Form 8-K, February 25, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

BIGGER CAPITAL FUND L P also filed stake reports on 13 other companies ↓

Sell to companies like Dermata Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Out (departing)1
Latest filing2026-02-25

Dermata Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-25. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Dermata Therapeutics, Inc. files it.

Also on the record for Dermata Therapeutics, Inc.

DateRecordFigureOur pageSource
November 2, 2026Stake report, Schedule 13G, by Bigger Michael8.36% of the class5%+ stakesSource
June 1, 2026Stake report, Schedule 13D, by Kyri K. Van Hoose9% of the class5%+ stakesSource
May 13, 2026Stake report, Schedule 13G/A, by Mitchell P. Kopin4.99% of the class5%+ stakesSource
April 22, 2026Stake report, Schedule 13G/A, by BIGGER CAPITAL FUND L P1.87% of the class5%+ stakesSource
February 23, 2026Stake report, Schedule 13D/A, by PROEHL GERALD T17.3% of the class5%+ stakesSource
February 18, 2026Stake report, Schedule 13G/A, by Armistice Capital, LLC4.99% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Armistice Capital, LLC4.99% of the class5%+ stakesSource
February 9, 2026Stake report, Schedule 13G/A, by Bigger Michael9.89% of the class5%+ stakesSource
February 2, 2026Stake report, Schedule 13D/A, by PROEHL GERALD T19.6% of the class5%+ stakesSource
January 8, 2026Stake report, Schedule 13D/A, by PROEHL GERALD T24.7% of the class5%+ stakesSource
January 7, 2026Form D, private offering$4.12M soldForm D pageSource
January 2, 2026Stake report, Schedule 13G, by Mitchell P. Kopin5.5% of the class5%+ stakesSource

Selling to them or working with them? See who runs Dermata Therapeutics, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Dermata Therapeutics, Inc. and the records around it.

Dermata Therapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Dermata Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Dermata Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Dermata Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 15 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-25Out8-K, 2026-02-25

Why did they leave? What the filings say

For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.

Selling to Dermata Therapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on Dermata Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Dermata Therapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Dermata Therapeutics, Inc., with the record behind each one.

Find candidates like senior executive at Dermata Therapeutics, Inc.

Every change, in the filing's words

Filed 2026-02-25 · 8-K

Departing: Mary Fisher

Ms. Fisher resigned from the Board in order to comply with her employer recently being acquired and no longer permitting her to serve on the Company's Board.

Also stated in this filing

  • On February 23, 2026, Mary Fisher provided Dermata Therapeutics, Inc. (the "Company") with notice of her resignation from the Board of Directors (the "Board"), including from her role on any committees thereof, effective March 31, 2026.

Tools for this story

Each opens in a new tab, filled in for Dermata Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/dermata-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Dermata Therapeutics, Inc. executive departure 2026. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/dermata-therapeutics